These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 18555840

  • 1. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
    Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML.
    Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
    [Abstract] [Full Text] [Related]

  • 2. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
    Rosenson RS.
    Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
    Qin S, Liu T, Kamanna VS, Kashyap ML.
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2428-34. PubMed ID: 17872455
    [Abstract] [Full Text] [Related]

  • 4. Effect of rosuvastatin treatment on cholesterol efflux from human macrophages.
    Kralova Lesna I, Adamkova V, Pagacova L.
    Neuro Endocrinol Lett; 2011 Nov; 32 Suppl 2():24-8. PubMed ID: 22101878
    [Abstract] [Full Text] [Related]

  • 5. Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL.
    Marchesi M, Parolini C, Caligari S, Gilio D, Manzini S, Busnelli M, Cinquanta P, Camera M, Brambilla M, Sirtori CR, Chiesa G.
    Br J Pharmacol; 2011 Nov; 164(5):1460-8. PubMed ID: 21486287
    [Abstract] [Full Text] [Related]

  • 6. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
    Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K.
    Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2246-53. PubMed ID: 25104799
    [Abstract] [Full Text] [Related]

  • 7. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
    Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB.
    Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ.
    Am J Cardiol; 2007 Mar 01; 99(5):681-5. PubMed ID: 17317371
    [Abstract] [Full Text] [Related]

  • 9. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
    Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denèfle P, Staels B, Branellec D.
    J Clin Invest; 1996 Jun 01; 97(11):2408-16. PubMed ID: 8647932
    [Abstract] [Full Text] [Related]

  • 10. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
    Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM.
    Am J Cardiol; 2004 Jul 15; 94(2):157-61. PubMed ID: 15246890
    [Abstract] [Full Text] [Related]

  • 11. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
    Kang BY, Mehta JL.
    J Cardiovasc Pharmacol Ther; 2009 Dec 15; 14(4):283-91. PubMed ID: 19724024
    [Abstract] [Full Text] [Related]

  • 12. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
    Landsberger M, Jantzen F, Könemann S, Felix SB.
    Biochem Biophys Res Commun; 2005 Nov 04; 336(4):1005-9. PubMed ID: 16165089
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rapid response to lipids profile and leukocyte gene expression after rosuvastatin administration in Chinese healthy volunteers.
    Hua CX, Li YS, Liu YQ, Liu H, Li N, Wu Y, Xu L, Huang YL.
    Chin Med J (Engl); 2008 Jul 05; 121(13):1215-9. PubMed ID: 18710642
    [Abstract] [Full Text] [Related]

  • 15. [Receptors and molecular heterogeneity of lipoprotein particles containing apolipoprotein A-I].
    Broutin H, Puchois P, Ailhaud G, Barbaras R, Torpier G, Fruchart JC.
    Ann Biol Clin (Paris); 1988 Jul 05; 46(1):16-23. PubMed ID: 2839056
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
    Famer D, Crisby M.
    Neurosci Lett; 2007 May 23; 419(1):68-73. PubMed ID: 17433542
    [Abstract] [Full Text] [Related]

  • 18. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):327-32. PubMed ID: 18585701
    [Abstract] [Full Text] [Related]

  • 19. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.
    Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2009 Mar 20; 14(1):5-13. PubMed ID: 19246334
    [Abstract] [Full Text] [Related]

  • 20. [Rosuvastatin: pharmacologic features].
    Bernini F, Catapano AL.
    Ital Heart J; 2003 Dec 20; 4 Suppl 7():22S-32S. PubMed ID: 14983744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.